SERES THERAPEUTICS Cambridge, MA, USA
MICROBIOME – TRANSPLANT PATIENTS
Direct-Acting Microbiome-based Therapeutic
Seres Therapeutics is developing a novel class of medicines using live bacteria with the aim of modifying the human microbiome. The company’s R&D pipeline includes programs targeting infectious diseases, metabolic diseases, and inflammatory / immune diseases, including immuno-oncology. With CARB-X support, Seres is developing SER-155, a preclinical stage rationally-designed consortium of bacterial spores to improve outcomes in patients receiving stem cell or whole organ transplantation. SER-155 aims to reduce the risk of both graft vs. host disease and bacterial infection.
Current Development Stage: Pre-clinical
CARB-X Investment: Initial investment of up to $2.5m with potential option payments up to $3.1m.
Initial CARB-X Investment Date: October 1, 2017
Graduation Date: June 1, 2021